Fritextsökning
Innehållstyper
-
Novo Nordisk sues compounding pharmacies in the US
Novo Nordisk is suing compounding pharmacies in Florida, USA, because the company claims to have found impurities in the active ingredient in the obesity drug Wegovy.
-
Kennedy stoppar 22 projekt inom mRNA-vaccin – experter varnar för följderna
USA:s hälsodepartement avbryter finansieringen av 22 projekt som utvecklar mRNA-baserade vacciner, och växlar över till vad som hävdas vara ”säkrare och bredare...
-
EU Pharmaceutical Legislation Reform
The EU's Pharmaceutical Legislation Reform, proposed by the commission within the European Health Union, aims to establish a citizen-centric framework to enhanc...
-
Final assembly inspection of medical plastics
Technical paper by ZEISS Medical Industry Solutions.
-
“What is important is to create an overview and understanding from different perspectives”
Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...
-
Grönt ljus för Kennedy sänker läkemedelsbolag
Flera läkemedelsbolag backar på börsen efter att senatskommittén godkänt Robert F. Kennedy Jr som kandidat till landets hälsominister.
-
Digitala produktpass - från regelverk till konkurrensfördel
Inom EU pågår just nu en omfattande omställning mot mer cirkulära och hållbara affärsmodeller. En viktig pusselbit i detta arbete är införandet av digitala prod...
-
Marie Gårdmark: New incentives for orphan products on its way
"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...
-
Cellevate stärker ledningen – utnämner CTO
Biotechbolaget Cellevate utnämner Christel Fenge till Chief Technology Officer (CTO).
-
FDA approves first non-opioid pain reliever in over 20 years
For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.
-
New drug to simplify treatment of hemophilia
A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).
-
Anna Hellergård blir ny vd för Attana
Attana, som arbetar för att effektivisera utvecklingen av nya läkemedel, har utsett Anna Hellergård till ny vd med tillträde 1 april. Det framgår av ett pressmeddelande.
-
We desire talent to come here, but are we genuinely welcoming them?
Sweden faces significant challenges in creating a truly inclusive environment that makes international professionals feel welcome, valued, and able to build mea...
-
Norway rejects national life science strategy – sees no need
The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.
-
“A major energy boost for the entire cancer vaccine field”
The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...
-
19 medicines in Sweden are under investigation in a major EMA inquiry
19 medicines marketed in Sweden are affected by an ongoing extensive European investigation into suspected fraud at an Indian contract research organisation. Am...
-
Major advances in IVF labs in the last few decades
Since the introduction of in vitro fertilisation several decades ago, many developments have been made in the field, and the main part of that development has t...
-
Samuel Lagercrantz: We are currently seeing medical breakthroughs in these areas
Samuel Lagercrantz, Editor in Chief of Life Science Sweden, lists three medical fields in which we are currently seeing major breakthroughs and two fields in wh...
-
Ingrid Lönnstedt: Demystification of the power of a scientific study
”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...
-
EMA varnar för icke godkända cellterapier
Icke godkända, och därmed olagliga, avancerade terapiläkemedel marknadsförs till patienter i Europa. Det uppger den europeiska läkemedelsmyndigheten EMA, som nu...
-
Eli Lilly to build a USD 2.5-billion plant in Germany
US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...
-
Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell
Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Mich...
-
The future of healthcare in focus: ”Together, things happen”
In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...
BREAKING